Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to $1.8 million.

  • Korro Bio's Share-based Compensation rose 4336.21% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 6022.62%. This contributed to the annual value of $4.5 million for FY2024, which is 8740.03% up from last year.
  • Latest data reveals that Korro Bio reported Share-based Compensation of $1.8 million as of Q3 2025, which was up 4336.21% from $2.0 million recorded in Q2 2025.
  • Korro Bio's Share-based Compensation's 5-year high stood at $6.1 million during Q2 2021, with a 5-year trough of -$14.3 million in Q4 2022.
  • Its 5-year average for Share-based Compensation is $1.9 million, with a median of $1.8 million in 2025.
  • As far as peak fluctuations go, Korro Bio's Share-based Compensation tumbled by 37662.66% in 2022, and later soared by 21509.9% in 2024.
  • Over the past 5 years, Korro Bio's Share-based Compensation (Quarter) stood at $5.2 million in 2021, then plummeted by 376.63% to -$14.3 million in 2022, then soared by 108.59% to $1.2 million in 2023, then grew by 10.59% to $1.4 million in 2024, then soared by 34.49% to $1.8 million in 2025.
  • Its Share-based Compensation stands at $1.8 million for Q3 2025, versus $2.0 million for Q2 2025 and $1.8 million for Q1 2025.